APVO News and Press, Aptevo Therapeutics Inc. From 05/26/21

Dose Escalation Study of APVO436 Shows Favorable Safety Profile and No Severe Neutropenia, a Potentially Life-threatening Side Effect, Reported in a Significant Number of Patients Receiving CD123-Targeting Drugs Dosing Level Established For Advanced Clinical Trials SEATTLE, WA / A...

Aptevo Therapeutics (APVO): Q1 GAAP EPS of -$1.74 misses by $0.12.Revenue of $2.42M misses by $10.65M.Press Release For further details see: Aptevo Therapeutics EPS misses by $0.12, misses on revenue

Advances Phase 1/1b Study of APVO436 for Treatment of Acute Myeloid Leukemia and High-Grade Myelodysplastic Syndrome; Dosing in Cohort 10 Ongoing SEATTLE, WA / ACCESSWIRE / May 11, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or "the Company") (NASDAQ:APVO), a clinical-stage biotechnology ...

SEATTLE, WA / ACCESSWIRE / April 9, 2021 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR TM and ADAPTIR-FLEX TM platform technologies, today announced that it will p...

Aptevo Therapeutics (APVO): FY GAAP EPS of -$5.23 misses by $0.66.Revenue of $4.31M beats by $0.63M.Press Release For further details see: Aptevo Therapeutics EPS misses by $0.66, beats on revenue

Advances Phase 1/1b Study of APVO436 for Treatment of Acute Myeloid Leukemia and High-Grade Myelodysplastic Syndrome; Enrollment in Cohort 10 Ongoing Completes Sale of RUXIENCE Royalty Payments for Up Front Plus Milestone Payments of up to $67.5 million; Amends Non-Dilutive Term Loan Ag...

Today, we take our first look at a small developmental concern based out of Seattle called Aptevo. The stock was in the news of late last year,  thanks to a buyout offer and some trial developments. A full analysis on Aptevo Therapeutics follows in the paragraphs below. ...

Stockholders Are Not Required to Take Any Action at this Time SEATTLE, WA / ACCESSWIRE / February 9, 2021 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ an...

Click here to read the previous top NASDAQ biotech stocks article. It’s been a stellar year for the NASDAQ Biotechnology Index (INDEXNASDAQ: NBI ), which started at 3,763.05 points in January and reached a high of 4,811.03 points on December 15. While the inde...

Aptevo went up hugely on positive phase 1 data in AML. The company develops bispecific antibodies against cancer. Although early stage, this is a definite candidate for my watchlist. For further details see: Aptevo: Positive Early Stage Data Makes This Highly Interesting...